PHARMA LAENEN: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
PHARMA LAENEN
Largest movements
- Cash -€35,091
down €35,091 (-44.2%), from €79,331 to €44,240
mainly Contributions, distributions and other (-€15,000) and Net result for the year (-€9,012)
- Receivables within one year +€6,209
up €6,209 (+244%), from €2,542 to €8,751
of which Other amounts receivable: +€6,209
- Tangible fixed assets +€1,843
up €1,843 (+18.9%), from €9,746 to €11,589
- Reserves -€24,012
down €24,012 (-44.6%), from €53,881 to €29,869
- Tax, wage and social debts -€3,886
down €3,886 (-60.9%), from €6,377 to €2,490
- Other debts +€2,990
up €2,990 (+30.6%), from €9,760 to €12,750
- Trade debts -€2,080
down €2,080 (-66.5%), from €3,131 to €1,050
- Gross operating margin -€15,279
down €15,279, from €12,387 to -€2,891
- Taxes -€2,205
down €2,205 (-90.2%), from €2,446 to €240
- Depreciation +€661
up €661 (+20.7%), from €3,195 to €3,856
- Other operating charges +€464
up €464 (+34.1%), from €1,361 to €1,826
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €91,748 | €64,760 | -€26,988 | -29.4% |
| Fixed assets | 21/28 | €9,746 | €11,589 | +€1,843 | +18.9% |
| Tangible fixed assets | 22/27 | €9,746 | €11,589 | +€1,843 | +18.9% |
| Furniture and vehicles | 24 | €9,746 | €11,589 | +€1,843 | +18.9% |
| Current assets | 29/58 | €82,002 | €53,171 | -€28,831 | -35.2% |
| Amounts receivable within one year | 40/41 | €2,542 | €8,751 | +€6,209 | +244% |
| Trade receivables | 40 | €1,987 | €1,987 | = | 0.0% |
| Other amounts receivable | 41 | €554 | €6,763 | +€6,209 | +1,120% |
| Cash at bank and in hand | 54/58 | €79,331 | €44,240 | -€35,091 | -44.2% |
| Deferred charges and accrued income | 490/1 | €130 | €180 | +€51 | +38.9% |
| Total equity and liabilities | 10/49 | €91,748 | €64,760 | -€26,988 | -29.4% |
| Equity | 10/15 | €72,481 | €48,469 | -€24,012 | -33.1% |
| Contributions | 10/11 | €18,600 | €18,600 | = | 0.0% |
| Reserves | 13 | €53,881 | €29,869 | -€24,012 | -44.6% |
| Distributable reserves | 133 | €53,881 | €29,869 | -€24,012 | -44.6% |
| Amounts payable | 17/49 | €19,267 | €16,291 | -€2,977 | -15.4% |
| Amounts payable within one year | 42/48 | €19,267 | €16,291 | -€2,977 | -15.4% |
| Trade debts | 44 | €3,131 | €1,050 | -€2,080 | -66.5% |
| Suppliers | 440/4 | €3,131 | €1,050 | -€2,080 | -66.5% |
| Taxes, remuneration and social security | 45 | €6,377 | €2,490 | -€3,886 | -60.9% |
| Taxes | 450/3 | €6,377 | €2,490 | -€3,886 | -60.9% |
| Other amounts payable | 47/48 | €9,760 | €12,750 | +€2,990 | +30.6% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €3,195 | €3,856 | +€661 | +20.7% |
| Other operating charges | 640/8 | €1,361 | €1,826 | +€464 | +34.1% |
| Gross operating margin | 9900 | €12,387 | -€2,891 | -€15,279 | |
| Operating profit (loss) | 9901 | €7,831 | -€8,573 | -€16,404 | |
| Financial income | 75/76B | €4 | - | -€4 | |
| Recurring financial income | 75 | €4 | - | -€4 | |
| Financial charges | 65/66B | €121 | €198 | +€77 | +63.9% |
| Recurring financial charges | 65 | €121 | €198 | +€77 | +63.9% |
| Profit (loss) for the period before taxes | 9903 | €7,713 | -€8,771 | -€16,485 | |
| Income taxes | 67/77 | €2,446 | €240 | -€2,205 | -90.2% |
| Profit (loss) for the period | 9904 | €5,268 | -€9,012 | -€14,279 | |
| Profit (loss) for the period to be appropriated | 9905 | €5,268 | -€9,012 | -€14,279 |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 15 October 2026 via checked.be.